Development of an adverse outcome pathway network for nephrotoxicity

Arch Toxicol. 2024 Mar;98(3):929-942. doi: 10.1007/s00204-023-03637-7. Epub 2024 Jan 10.

Abstract

Adverse outcome pathways (AOPs) were introduced in modern toxicology to provide evidence-based representations of the events and processes involved in the progression of toxicological effects across varying levels of the biological organisation to better facilitate the safety assessment of chemicals. AOPs offer an opportunity to address knowledge gaps and help to identify novel therapeutic targets. They also aid in the selection and development of existing and new in vitro and in silico test methods for hazard identification and risk assessment of chemical compounds. However, many toxicological processes are too intricate to be captured in a single, linear AOP. As a result, AOP networks have been developed to aid in the comprehension and placement of associated events underlying the emergence of related forms of toxicity-where complex exposure scenarios and interactions may influence the ultimate adverse outcome. This study utilised established criteria to develop an AOP network that connects thirteen individual AOPs associated with nephrotoxicity (as sourced from the AOP-Wiki) to identify several key events (KEs) linked to various adverse outcomes, including kidney failure and chronic kidney disease. Analysis of the modelled AOP network and its topological features determined mitochondrial dysfunction, oxidative stress, and tubular necrosis to be the most connected and central KEs. These KEs can provide a logical foundation for guiding the selection and creation of in vitro assays and in silico tools to substitute for animal-based in vivo experiments in the prediction and assessment of chemical-induced nephrotoxicity in human health.

Keywords: Adverse outcome pathway; Key events; Molecular initiating event; Nephrotoxicity; New approach methodology.

MeSH terms

  • Adverse Outcome Pathways*
  • Animal Experimentation*
  • Animals
  • Drug-Related Side Effects and Adverse Reactions*
  • Humans
  • Renal Insufficiency*
  • Risk Assessment / methods